|
To,
Dr. Amey Mane,
Sun Pharma Laboratories Ltd.,
Sun House, 201 B/1, Western Express Highway, Goregaon (East), Mumbai,
Maharashtra (India) – 400 063
Dear Dr. Mane,
Subject: Assessment of drug utilization pattern of Sacubitril/Valsartan in Indian heart failure patients
(SECURE)
In response to your letter dated _________, I give my consent to participate in the above captioned
study bearing protocol number SP/CVD/SECURE/RWE-10-2023.
I understand that:
-
You will provide me with a copy of the study Protocol and the requisite number of Data Collection
forms (DCFs)
-
The DCFs will capture data as defined in the Protocol, including laboratory results as prescribed
and performed in accordance with my routine clinical practice and no fresh laboratory or any
investigations will be conducted for the said study
-
The patient’s identity shall not be disclosed in the DCF
-
I will ensure to capture all available information accurately and completely in the DCF provided
-
I understand and agree to allow an independent CRO to visit the study center and compare the
information supplied in the DCF to that in medical records
My personal details are given below for accuracy of your records.
|
}}){kind=logo}